

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

Eveline Barbieri,^{1,2} Parth Mehta,¹ Zaowen Chen,¹ Linna Zhang,¹ Andrew Slack,¹ Stacey Berg,¹ and Jason M. Shohet¹

¹Texas Children's Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas and ²Department Hematology-Oncology, University of Bologna, Bologna, Italy

Abstract

Novel therapeutic approaches are urgently needed for high-stage neuroblastoma, a major therapeutic challenge in pediatric oncology. The majority of neuroblastoma tumors are p53 wild type with intact downstream p53 signaling pathways. We hypothesize that stabilization of p53 would sensitize this aggressive tumor to genotoxic chemotherapy via inhibition of MDM2, the primary negative upstream regulator of p53. We used pharmacologic inhibition of the MDM2-p53 interaction with the small-molecule inhibitor Nutlin and studied the subsequent response to chemotherapy in neuroblastoma cell lines. We did 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and terminal deoxynucleotidyl transferase assays to measure proliferation and apoptosis in several cell lines (IMR32, MYCN3, and JF) treated with combinations of cisplatin, etoposide, and Nutlin. We found consistent and robust decreases in proliferation and increases in apoptosis with the addition of Nutlin 3a to etoposide or cisplatin in all cell lines tested and no response to the inactive Nutlin 3b enantiomer. We also show a rapid and robust accumulation of p53 protein by Western blot in these cells within 1 to 2 hours of treatment. We conclude that MDM2 inhibition dramatically enhances the activity of genotoxic drugs in neuroblastoma and should be considered as an adjuvant to chemotherapy for this aggressive pediatric cancer and for possibly other p53 wild-type solid tumors. [Mol Cancer Ther 2006;5(9):2358–65]

Received 5/23/06; revised 7/7/06; accepted 7/26/06.

Grant support: Gilson Logenbaugh Foundation, the Hope Street Kids Foundation, and NIH K08-CA090517 (J.M. Shohet).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: E. Barbieri and P. Mehta contributed equally to this work.

Requests for reprints: Jason M. Shohet, Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, 1102 Bates Street, Houston TX 77030. Phone: 832-824-4723;

Fax: 832-825-4732. E-mail: jmshohet@texachildrenshospital.org

Copyright © 2006 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-06-0305

Introduction

Neuroblastoma is an aggressive pediatric malignancy accounting for >15% of all pediatric cancer deaths and represents a major therapeutic challenge in pediatric oncology (1, 2). Current therapy is inadequate for high-stage disease with <40% long-term survival and is associated with unacceptable dose-related toxicity (3). Aberrant expression of the *MYCN* oncogene plays a central role in neuroblastoma tumorigenesis and *MYCN* amplification is a major negative prognostic indicator (1, 4, 5). As part of our investigations into the molecular effectors of *MYCN* action, we found that *MYCN* regulates the *MDM2* gene, which, in turn, inhibits the p53 tumor suppressor (6). Because the overwhelming majority of *de novo* neuroblastoma tumors are wild type at the p53 locus (7–9), we hypothesized that MDM2-mediated inhibition of p53 plays an important role in preventing apoptosis in neuroblastoma and contributes to disease progression. We also predicted that pharmacologic disruption of the interaction between MDM2 and p53 would disinhibit p53 sufficiently to activate downstream apoptotic pathways in neuroblastoma.

The tumor suppressor p53 is a central regulatory molecule responsible for growth arrest upon cellular stress or DNA damage (10, 11). In the event of extensive DNA damage, p53 activates apoptotic pathways leading to cell death. The fact that ~50% of all human tumors harbor p53 mutations underscores the importance of disrupting p53 activity in the process of tumorigenesis and progression (5). In addition to the paucity of p53 mutations in neuroblastoma (8, 12), several studies have also shown that p53 downstream functions are intact in neuroblastoma and that, when activated, p53 is capable of inducing normal apoptotic responses to stress or DNA damage (7–9). Thus, it is likely that the signals activating or inhibiting p53 in neuroblastoma need to be altered to permit tumorigenesis (13).

The primary negative regulator of p53 is MDM2 (14). Through direct binding to p53, MDM2 initiates p53 ubiquitination, nuclear export, and inactivation of p53 transactivating functions (10, 15). Interestingly, p53 directly activates *MDM2* transcription, leading to increased protein levels and decreased p53 function (10). This negative feedback loop is essential for controlled activation of p53 in cells that have limited damage and can self-repair. However, overexpression of MDM2 leads to insufficient p53 activity and contributes to tumorigenesis as shown in transgenic mouse models (16, 17) and in human tumors (5, 18). *MDM2* is amplified in over one third of sarcomas that retain wild-type p53 (19). Several studies have also shown that *Mdm2* haploinsufficiency prevents tumorigenesis in the E μ -myc mouse model of lymphoma (20, 21). These studies, in particular, showed that B-cell apoptosis was enhanced by *Mdm2* deficiency, resulting in reduced tumor formation and increased survival (22).

Pharmacologic inhibition of the MDM2-p53 interaction as a therapeutic approach is a subject of intense investigation (23–25). Recently, effective small-molecule inhibitors that competitively bind to MDM2 and prevent binding with p53 have been synthesized (23–25). In particular, the Nutlin compounds (e.g., Nutlin 3a and Nutlin 3b) were found to bind with high affinity to MDM2 and to inhibit the growth of p53 wild-type osteosarcoma xenografts (26). These compounds were identified in a high-throughput screen of MDM2 inhibitors, aided by high-resolution nuclear magnetic resonance structural analysis of the MDM2-p53 protein/protein interaction (ref. 24 and references therein).

Because MDM2-mediated ubiquitination of p53 is critical for initiation of p53 degradation, preventing the interaction of p53 and MDM2 leads to markedly diminished p53 degradation. Subsequent elevated levels of p53 can alter the transcriptional activity of p53 and induce cell cycle arrest (primarily through p21-mediated mechanisms) and apoptosis through transcriptionally dependent and independent mechanisms (27–29). These mechanisms have been shown to be primarily independent of p53 phosphorylation, because Nutlin treatment alone does not induce phosphorylation at p-Ser-15 (26) and earlier work showed that p53 phosphorylation is dispensable for p53-mediated transcriptional activation and apoptosis (30).

As a therapeutic modality, disrupting the interaction of MDM2 and p53 shows great promise. Nutlin 3a has been shown to be antiproliferative as a single agent in a variety of adult tumors with wild-type p53. These include chronic lymphocytic leukemia (31), acute myelogenous leukemia (32), lung cancer (33), as well as osteosarcoma and colon cancer (26, 27). As MDM2 inhibitors move to the clinic, reactivating p53 in tumors that have suppressed its antiproliferative activity may prove to be an important adjuvant to chemotherapy, sensitizing tumor cells to apoptosis in the presence of genotoxic damage (see refs. 25, 34 for recent reviews).

To test our hypothesis that neuroblastoma is sensitive to MDM2 inhibition, we studied the response of neuroblastoma cell lines to genotoxic chemotherapy with and without this treatment. Nutlin 3a, as a single agent, rapidly stabilized p53 and triggered cell death. Furthermore, we show that Nutlin-induced p53 stabilization dramatically sensitizes neuroblastoma cells to the effects of cisplatin and etoposide, resulting in apoptosis. Our data support the therapeutic use of MDM2 antagonists as agents used in combination with genotoxic drugs in the treatment of neuroblastoma.

Materials and Methods

Tissue Culture

The Tet21 and MYCN-3 were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% Tet-approved fetal bovine serum and 1% penicillin and streptomycin. The Tet21 cell line was obtained from Manfred Schwab (University of Heidelberg, Heidelberg,

Germany). The MYCN-3 cell line was generated as follows: the MYCN cDNA was cloned into the pTRE2-Hygro vector (BD Biosciences, Bedford, MA) containing a tetracycline-responsive promoter. This construct was then transfected into a SHEP subclone stably expressing the TRE-response element and selected with hygromycin. The JF, IMR32, and HCT 116 lines were maintained in RPMI 1640 (Invitrogen), MEM α (Invitrogen), McCoy's 5A medium, respectively, supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cisplatin solution (50 mg/mL; American Pharmaceutical Partners, Inc., Los Angeles, CA) and etoposide (Sigma, St. Louis, MO), stored as a 50 mmol/L stock solution in DMSO at -20°C , were used. Nutlin 3a and 3b were provided by Dr. Vassilev (Roche, Nutley, NJ). All the drugs were diluted in serum-free medium before treatment of cells.

Western Blot

Antibodies used are as follows: α -p53 (Santa Cruz Biotechnology, Santa Cruz, CA), α -MDM2 (Calbiochem, San Diego, CA), α -actin (Sigma) monoclonal antibodies, and horseradish peroxidase-conjugated goat α -mouse (Sigma) antibody were used for Western blot analysis as described below.

Fifty-microgram aliquots of protein from cells treated with Nutlin and combinations of chemotherapy (see Results) were electrophoresed and transferred as described (6). Cells were directly lysed by boiling in MDM2 lyses buffer for 5 minutes and protein was quantified by Bradford assay before electrophoresis. Actin was used for loading control in all experiments.

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were done as in ref. (35). Briefly, 0.5×10^5 cells/mL were plated into 96-well microtiter plates, incubated at 37°C , and cultured overnight. Stock solutions of Nutlin 3a or 3b in DMSO were diluted in PBS and added to the appropriate concentration by serial dilutions. PBS alone, medium alone, and medium plus DMSO were control wells for each dilution. Plates were incubated for 72 hours and then centrifuged for 5 minutes at 1,000 rpm. Half the medium (135 μL) was removed and replaced with fresh medium. Then, 15 μL MTT were added to each well. Plates were shaken in the dark for 5 minutes, incubated for an additional 4 hours, and read at 550 nm in the plate reader.

Terminal Deoxynucleotidyl Transferase Apoptosis Assay

IMR32, JF, and MYCN3 cells were plated in 10-cm dishes at 2 million cells per dish and grown overnight. The cells were exposed to drug combinations for 24 hours. Briefly, cells were harvested in $1 \times$ PBS and incubated in 3 mL of 1% formaldehyde-PBS for 15 minutes on ice. The cells were fixed in 70% ethanol-PBS overnight at -20°C . Next, 50 λ of the terminal deoxynucleotidyl transferase (TdT) reaction mix were added to each sample consisting of 10 λ of $5 \times$ reaction buffer, 1.5 λ TdT, 5 λ CoCl_2 , 0.5 λ biotin-16-dUTP, and 33 λ dH_2O . The samples were incubated for 1 hour at

37°C and then washed with PBS. For fluorescence-activated cell sorting analysis, 100 λ avidin FITC buffer [4 \times SSC, 2.5 μ g/mL avidin DCS FITC (Vector Laboratories, Burlingame, CA), 0.1% Triton X-100, and 5% nonfat dry milk] was then added to each sample. The samples were incubated in the dark at room temperature for 30 minutes and washed in 1 mL 1 \times PBS + 0.1% Triton X-100. The cells were resuspended in PBS and transferred through a 70 μ m cell filter into a fluorescence-activated cell sorting tube for analysis. Fluorescence-activated cell sorting analysis was done using CellQuestPro and standard software.

Results

Nutlin 3a Shows a Specific Antitumor Activity through p53 Stabilization in Neuroblastoma Cells

We first tested the ability of the active Nutlin enantiomer, Nutlin 3a, to activate the p53 pathway in neuroblastoma cells. Western blot analysis showed that Nutlin 3a is able to induce a strong, specific, and rapid stabilization of p53 in neuroblastoma cell lines (Fig. 1A and B). We used the inactive enantiomer, Nutlin 3b, which has \sim 200-fold lower MDM2 binding affinity, as a control for off-target drug effects (26).

Because neuroblastoma is treated with multidrug chemotherapy, we also wanted to test the effect of Nutlin combined with agents commonly used for neuroblastoma treatment. Incubation of exponentially growing IMR32 cells

with a low (2 μ mol/L) or high dose (10 μ mol/L) of Nutlin 3a for 1 hour led to a significant increase in p53 protein level. In contrast, cisplatin or cisplatin plus Nutlin 3b had little effect on the p53 level. However, the low dose of Nutlin 3a significantly increased stabilization of cisplatin-induced p53. Nutlin 3b had no effect on p53 levels, as previously shown (Fig. 1A and B).

Because p53 stabilization plays a critical role in regulating both cell proliferation and apoptosis, we next examined the effect of the MDM2 inhibitor on these cell activities. IMR32 cells were treated with increasing doses of Nutlin 3a or Nutlin 3b, and cell viability and apoptosis were assessed by MTT and TdT assays, respectively. The analysis of cell growth and viability showed a potent and dose-dependent antiproliferative activity of the active enantiomer A compared with the enantiomer B (IC₅₀ 3.25 versus 52 μ mol/L), confirming the selective modulation of the p53 pathway by Nutlin 3a (Fig. 1C). Similarly, Nutlin 3a induces a significant and dose-dependent apoptotic effect as a single agent. No apoptosis was observed with Nutlin 3b at these doses (Fig. 1D).

Nutlin 3a Potentiates the Antitumor Effects of Conventional Chemotherapeutic Agents in Neuroblastoma Cells

Next, we tested the effects of the combined treatment of Nutlin and cisplatin on cell growth viability and apoptosis to determine if inhibition of the p53-MDM2 interaction might potentiate the antitumor effect of conventional





Figure 1. **A**, Nutlin-mediated apoptosis occurs through the p53 pathway. Active enantiomer 3a activates p53 pathway in IMR32 cell line. IMR32 cells were incubated with low-dose cisplatin (CDDP) alone (33 nmol/L) or in combination with Nutlin (N3a/N3b) for 1 h, and p53 and actin proteins were analyzed in cell lysates by Western blotting. This rapid response to Nutlin contrasts with that in other cell lines from adult tumors recently published in the literature (27). **B**, no effect of Nutlin 3b on p53 protein compared with Nutlin 3a and control untreated cells. **C** and **D**, blockade of p53-MDM2 interaction reduces cell viability of neuroblastoma cell lines in a dose-dependent manner. The inactive enantiomer 3b did not affect cell growth, confirming the selective modulation of the p53 pathway by Nutlin 3a. IMR32 cells were incubated with increasing concentrations of Nutlin 3a or 3b (0.2 – 100 μ mol/L) for 72 h and the cell viability was determined by the MTT assay (**C**). IMR32 cells were further incubated with the indicated concentrations (1 – 10 μ mol/L) of Nutlin 3a or 3b for 24 h and the apoptosis percentage was measured using the TdT method (**D**). *, statistically significant at $P < 0.05$.

Figure 2. The active enantiomer 3a potentiates the antiproliferative effects of conventional chemotherapeutic agents in neuroblastoma cell lines. The inactive enantiomer 3b does not modify the dose-response curve of cisplatin alone. Three neuroblastoma cell lines (IMR32, JF, and MYCN3) were exposed to increasing doses of cisplatin alone or in combination with low dose (2 $\mu\text{mol/L}$) of Nutlin 3a or 3b for 72 h. Cell survival percentage was determined using MTT assay.



chemotherapy in neuroblastoma. Both N-type (neuronal) IMR32 and JF, and S-type (stromal) MYCN3, were simultaneously treated with increasing low dose of cisplatin and fixed low dose (2 $\mu\text{mol/L}$) of active or inactive enantiomer of Nutlin 3 for 72 hours. MTT analysis showed that treatment with Nutlin 3a plus cisplatin significantly reduced cell viability in all cell lines compared with treatment with cisplatin alone (Fig. 2). The Nutlin 3b control showed no effect. IC_{50} values in different neuroblastoma cell lines after single-agent or combined treatment are summarized in Table 1. The matched p53 wild-type HCT116+ and p53 null HCT116- cell lines were also tested to confirm the expected p53-dependent activity of Nutlin. Because MYCN expression can increase *MDM2* expression, two MYCN-inducible cell lines, Tet21 and MYCN3, were tested to determine if changes in MYCN level altered the response to Nutlin. The IC_{50} did not change significantly upon MYCN induction, suggesting that the effect of Nutlin was sufficiently potent at these doses to overcome the 2- to 3-fold increase in *MDM2* seen upon MYCN induction in these cell lines (Table 1; ref. 6). To assess the contribution of low dose of Nutlin 3a to apoptosis induced by chemotherapy, we did TdT assays after treatment with Nutlin 3a or Nutlin 3b plus chemotherapy. IMR32 cells were incubated with increasing doses of cisplatin or etoposide for 24 hours. TdT analysis shows that the addition of low-dose Nutlin 3a consistently increases apoptosis in combination with etoposide (Fig. 3A) or cisplatin (Fig. 3B). We showed a similar effect in the JF and MYCN3 cell lines as shown in Fig. 4A. Thus, our data show that the addition of Nutlin 3a to chemotherapy both decreases cell viability as measured by MTT assay and increases sensitivity to apoptosis due to genotoxic chemotherapy.

Because combined cisplatin and etoposide is commonly used for induction therapy in neuroblastoma (1), we further tested this combination plus Nutlin 3a (Fig. 4B). Although the addition of etoposide to cisplatin increased apoptosis at 24 hours, a dramatic increase was noted upon addition of Nutlin 3a. It should be emphasized that the doses of cisplatin and etoposide used in these studies induced

minimal apoptosis as single agents. Figures 3 and 4 illustrate that further stabilization of p53 with inhibition of *MDM2* significantly sensitizes neuroblastoma to these chemotherapeutic agents.

Nutlin 3a-Mediated Apoptosis Occurs through Rapid p53 Stabilization in Neuroblastoma Cells

To further define the mechanism of action of Nutlin 3a in neuroblastoma, we analyzed p53 protein levels in IMR32 cells at different time points after treatment. IMR32 cells were incubated with low-dose cisplatin; Nutlin 3a or 3b alone; or in combination for 1, 4, and 8 hours. p53 expression was then assayed by immunoblot. Treatment with higher doses of Nutlin 3a (10 $\mu\text{mol/L}$) was included as a positive control for p53 stabilization. We show that increases in p53 protein levels could be detected as early as 1 hour after exposure to Nutlin 3a (Fig. 5A). We also show increased *MDM2* levels at 4 hours resulting from p53-driven expression of *MDM2* (Fig. 5B). These findings

Table 1. IC_{50} values ($\mu\text{mol/L}$) for single-agent or combined treatment in neuroblastoma cells

Cell line	Cisplatin	Nutlin 3a	Nutlin 3b	Cis + Nut3a	Cis + 3b
HCT116 wt	7	3.5		0.39	
HCT116 null	7.5	40		4	
IMR-32	0.5	3.02	51.6	0.01	0.5
JF	0.8	2.5		0.09	0.7
Tet21 Ind	21.5	5	>100*	6.25	20.3
Tet21-NI	23.8	20	>100*	20.3	20.3
MYCN3-Ind	1.13	3	31.5	0.09	1.13
MYCN3-NI	4	3	31.5	0.17	1.5

NOTE: Data were derived from MTT assays done as described in Materials and Methods. Tet 21 and MYCN 3 are tet-inducible cell lines. IMR-32 and JF (SK-N-JF) are MYCN-amplified cell lines. Nutlin 3a consistently reduced the IC_{50} of cisplatin between 10- and 50-fold depending on cell lines tested. Although less sensitive to cisplatin than the other cell lines, there is a trend toward increased sensitivity in the MYCN-induced version of the Tet21 cell line.

Abbreviations: Ind, induced; NI, noninduced; wt, wild type.

*The highest dose tested was 100 $\mu\text{mol/L}$.




Figure 3. The active enantiomer 3a potentiates the proapoptotic effects of conventional chemotherapeutic agents in IMR32 cell line. IMR32 cells were incubated with increasing low-dose etoposide (VP-16; range 0.1–1 $\mu\text{mol/L}$) or cisplatin (range 0.02–0.7 $\mu\text{mol/L}$) alone or in combination with low dose (2 $\mu\text{mol/L}$) of Nutlin 3a for 24 h. Apoptosis percentage was determined using TdT method and FITC-positive fractions were measured by flow cytometry. *, statistically significant at $P < 0.05$.

illustrate that the expected dynamic autoregulation of MDM2 by p53, and p53 by MDM2 (36), is active in neuroblastoma. Nutlin 3a and cisplatin treatment yielded higher p53 levels than Nutlin alone consistent with the apoptosis data (Figs. 3 and 4), and Nutlin 3b did not affect p53 levels as shown previously (Fig. 5C).

It is likely that the early rapid increase in p53 seen with Nutlin 3a leads to irreversible activation of the apoptotic pathway before the later increase in MDM2 levels can down-regulate this response in neuroblastoma cells.

Discussion

Our results show that targeting of the p53-MDM2 interaction with MDM2 inhibitors limits proliferation and sensitizes neuroblastoma cells to drug-induced apoptosis. The presence of wild-type p53 in the majority of neuro-

blastomas at diagnosis (13) represents a potent molecular target for therapy. p53 controls the activity of multiple genes involved in cell cycle, apoptosis, and cell senescence regulation (for review, see ref. 10). One major function of p53 is activation of the G₁-S and G₂-M checkpoints of the cell cycle through transcriptional stimulation of *p21* (for review, see ref. 37). A second important function is that p53 transcriptionally activates multiple proapoptotic pathways (such as those downstream of BAX), which forms mitochondrial pores leading to release of cytochrome *c*, activating downstream caspases leading to apoptosis (38). Not only is p53 not mutated in neuroblastoma, but also




Figure 4. A, Nutlin 3a potentiates the proapoptotic effects of cisplatin in multiple cell lines. Three neuroblastoma cell lines [IMR32, JF, and MYCN3 (MYCN conditional)] were exposed to the indicated concentrations of cisplatin alone or in combination with low dose (2 $\mu\text{mol/L}$) of Nutlin 3a for 24 h. B, Nutlin 3a potentiates the proapoptotic effects of a common cytotoxic combination in IMR32 cell line. IMR32 cells were incubated with low dose (0.1 $\mu\text{mol/L}$) of etoposide alone, in combination with low dose (0.5 $\mu\text{mol/L}$) of cisplatin, or in combination with low dose of cisplatin and Nutlin 3a (triple therapy) for 24 h. Apoptosis percentage was measured by TdT assay and FITC-positive fractions by flow cytometry. *, statistically significant at $P < 0.05$. **, statistically significant compared with etoposide + cisplatin and etoposide alone at $P < 0.05$.




Figure 5. Kinetics of p53 accumulation after treatment with Nutlin 3a and cisplatin in IMR32 cell line. Induction of the downstream target MDM2 is strictly correlated with the induction of p53: Western analysis for p53 (**A**) and MDM2 (**B**) was done in IMR32 cells after 1, 2, 4, and 8 h of incubation with cisplatin (0.03 $\mu\text{mol/L}$), Nutlin 3a (2 or 10 $\mu\text{mol/L}$), or combined treatment (cisplatin and low dose of enantiomer A or B). β -Actin was used to confirm equal loading of proteins. Nutlin 3b had no effect either alone or in combination (**A** and **C**).

these downstream pathways are functional (8, 12, 39–41). These findings suggest that upstream inhibition of p53 activation in the face of ongoing metabolic stress is necessary for circumvention of p53-mediated cell cycle arrest and apoptosis in rapidly proliferating neuroblastoma cells.

As a key oncogene driving the development of neuroblastoma, MYCN transcriptionally activates MDM2 expression (6), suggesting that elevated MDM2 partially contributes to controlling p53 activity in neuroblastoma, both during tumorigenesis and progression. The importance of MDM2 in neuroblastoma is an area of active

research. For example, Keshelava et al. (42) has shown elevated MDM2 expression is associated with multidrug resistance in some neuroblastoma lines. Other studies have shown that MDM2 degrades wild-type p53 in neuroblastoma cells (9, 43). Isaacs et al. (44) has shown the importance of MDM2 activity in neuroblastoma by showing that its ubiquitin ligase activity is rate limiting in the degradation of p53 in neuroblastoma. In addition, relapsed neuroblastoma has an increased frequency of MDM2 amplification (45). Taken together with the data presented above, these findings show that the p53-MDM2 pathway is intact in neuroblastoma and that disruption of the p53-MDM2 interaction in the presence of functional downstream pathways causes cell cycle arrest and apoptosis in neuroblastoma cells.

To date, the Nutlin compounds have been used to show effective cell cycle arrest and apoptosis upon disruption of MDM2-p53 in other p53 wild-type adult tumors [e.g., chronic lymphocytic leukemia (31), multiple myeloma (46), and lung cancer (33)], and p53 wild-type osteosarcoma (26). In these other tumors, maximum levels of p53 and rates of apoptosis are found after 24 to 48 hours of treatment (27). We find much more rapid and robust levels of p53 stabilization in neuroblastoma that suggests to us that neuroblastoma is particularly sensitive to this approach. Furthermore, because >98% of neuroblastoma has functional p53, MDM2 inhibition should be applicable to all neuroblastoma tumors during initial therapy.

MYCN is necessary and sufficient for tumorigenesis in a tissue-specific mouse model of neuroblastoma (47). In concordance with the human data, the majority of tumors from these mice are p53 wild type.³ The mechanism by which MYCN contributes to evasion of p53-directed apoptosis in neuroblastoma is still undefined. We have presented data supporting the hypothesis that MYCN-driven expression of MDM2 contributes to p53 inhibition in neuroblastoma (13). There are several studies in the literature suggesting that MYCN both sensitizes cells to apoptosis and permits proliferation and expansion of neuroblastoma cells (reviewed in refs. 8, 48). MYCN can sensitize cells to cytotoxic drug-induced apoptosis (49). Additionally, MYCN induces apoptosis in B lymphocytes when expressed from the immunoglobulin enhancer E_{μ} in transgenic mice (50).

In light of the pleotropic effects of MYCN influence on both apoptosis and proliferation, we expected to see a change in apoptosis response to Nutlin upon MYCN induction in our conditional cell lines. However, no significant change was seen in the two MYCN-inducible cell lines used in this study. We speculate that MYCN changes in apoptosis sensitivity are overridden by removal of MDM2-mediated suppression of p53. Alternatively, these SHEP-derived lines do not accurately reflect the

³Dr. Michael Hogarty, Children's Hospital of Philadelphia, personal communication.

sensitivity of *de novo* MYCN-amplified tumors. However, it is clear that all neuroblastoma cell lines tested, independent of their MYCN status, were extremely sensitive to combined therapy.

In this study, we show that Nutlin 3a causes growth inhibition of neuroblastoma cells. In the presence of genotoxic stress with cisplatin, Nutlin 3a induces between an 8- and 50-fold change in IC₅₀ compared with cisplatin alone. We further show that Nutlin 3a induces apoptosis in all the neuroblastoma cell lines tested. Moreover, addition of Nutlin 3a results in a marked decrease in the dose of the two genotoxic drugs, cisplatin and etoposide, required to induce apoptosis in these cells, broadening the therapeutic index of these drugs. Our data are particularly significant in light of the deleterious side effects of current therapy for neuroblastoma. These morbidities include cardiac dysfunction, sensorineural deafness, second malignancies, and growth disturbances (1, 3, 51, 52). The possibility of improved neuroblastoma cell kill in conjunction with attenuated morbidity in children with neuroblastoma warrants further investigation of these compounds in *in vivo* models and possibly clinical pilot studies.

Acknowledgments

We thank Dr. Susan Blaney (Baylor College of Medicine, Houston, TX) and Dr. Andrea Pession (University of Bologna, Bologna, Italy) for their advice and review of the data. We also acknowledge Dr. Lyubomir Vassilev (Hoffmann-La Roche, Nutley, NJ) for his advise and review of the manuscript.

References

- Matthay KK, Villablanca JG, Seeger RC, et al.; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-*cis*-retinoic acid. *N Engl J Med* 1999;341:1165–73.
- Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. *Lancet Oncol* 2005;6:649–58.
- Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. *Pediatr Blood Cancer* 2005;45:324–32.
- Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. *J Clin Oncol* 1998;16:3286–94.
- Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res* 2000;77:81–137.
- Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. *Proc Natl Acad Sci U S A* 2005;102:731–6.
- Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. *Nat Rev Cancer* 2005;5:876–85.
- Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. *Cancer Lett* 2003;197:173–9.
- Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. *Am J Pathol* 1996;148:1381–5.
- Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. *Oncogene* 2005;24:2899–908.
- Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. *Br J Cancer* 2001;85:1813–23.
- Hosoi G, Hara J, Okamura T, et al. Low frequency of the p53 gene mutations in neuroblastoma. *Cancer* 1994;73:3087–93.
- Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. *Cancer Lett* 2005;228:21–7.
- Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. *Curr Cancer Drug Targets* 2005;5:3–8.
- Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature* 1997;387:296–9.
- Alkhalaf M, Ganguli G, Messaddeq N, Le Meur M, Wasylyk B. MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. *Oncogene* 1999;18:1419–34.
- Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4. *Mol Cell Biol* 2006;26:192–8.
- Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. *Nucleic Acids Res* 1998;26:3453–9.
- Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. *Cell Mol Life Sci* 1999;55:96–107.
- Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. *Mol Cell Biol* 2001;21:5063–70.
- Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2–53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev* 1999;13:2658–69.
- Eischen CM, Alt JR, Wang P. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. *Oncogene* 2004;23:8931–40.
- Espinoza-Fonseca LM. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer. *Theor Biol Med Model* 2005;2:38.
- Fry DC, Graves B, Vassilev LT. Development of E3-substrate (MDM2–53)-binding inhibitors: structural aspects. *Methods Enzymol* 2005;399:622–33.
- Fry DC, Vassilev LT. Targeting protein-protein interactions for cancer therapy. *J Mol Med* 2005;83:955–63.
- Vassilev LT, Vu BT, Graves B, et al. *In vivo* activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 2004;303:844–8.
- Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. *Proc Natl Acad Sci U S A* 2006;103:1888–93.
- Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. *Cell Death Differ* 2006;13:994–1002.
- Inga A, Storic F, Darden TA, Resnick MA. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. *Mol Cell Biol* 2002;22:8612–25.
- Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. *J Biol Chem* 2004;279:53015–22.
- Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Mdm2 and Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. *Blood* 2006;108:993–1000.
- Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. *Blood* 2005;106:3150–9.
- Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. *Mol Cancer Ther* 2006;5:411–7.
- Stuhmer T, Bargou RC. Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies. *Cell Cycle* 2006;5:39–42.
- Zhang L, Plon SE, Nuchtern JG, et al. Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. *Anticancer Drugs* 2004;15:883–8.
- Iwakuma T, Lozano G. MDM2, an introduction. *Mol Cancer Res* 2003;1:993–1000.
- Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. *Oncogene* 2003;22:5834–47.
- Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell* 1995;80:293–9.

39. Vogan K, Bernstein M, Leclerc JM, et al. Absence of p53 gene mutations in primary neuroblastomas. *Cancer Res* 1993;53:5269–73.
40. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. *Cancer Lett* 2003;197:93–8.
41. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. *Med Pediatr Oncol* 2000;35:563–8.
42. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. *Cancer Res* 2001;61:6185–93.
43. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G₁ checkpoint function is attenuated. *Clin Cancer Res* 1999;5:4199–207.
44. Isaacs JS, Saito S, Neckers LM. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. *J Biol Chem* 2001;276:18497–506.
45. Carr J, Bell E, Pearson AD, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. *Cancer Res* 2006;66:2138–45.
46. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. *Blood* 2005;106:3609–17.
47. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. *EMBO J* 1997;16:2985–95.
48. Slack A, Shohet JM. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. *Cell Cycle* 2005;4:857–60.
49. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. *Oncogene* 1999;18:1479–86.
50. Zornig M, Busch G, Beneke R, et al. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca²⁺ fluxes. *Oncogene* 1995;11:2165–74.
51. Tang SQ, Huang DS, Wang JW, et al. [Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-*cis*-retinoic acid]. *Zhonghua Er Ke Za Zhi* 2004;42:486–9.
52. Holtta P, Alaluusua S, Saarinen-Pihkala UM, Wolf J, Nystrom M, Hovi L. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation. *Bone Marrow Transplant* 2002;29:121–7.